PTC Therapeutics Inc (PTCT) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of PTC Therapeutics Inc $159, price $62.34, upside +155.0%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch PTC Therapeutics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $18.07 – $89.55 · fair‑value band $79.50 – $288.23 · the $62.34 price screens below the $158.97 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow PTC Therapeutics in your weekly email
Every Wednesday you see whether PTC Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.
Show more
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Stock analysis
PTC Therapeutics Inc (PTCT) currently trades at $62.34, while our model-based Fair Value estimate is $158.97, implying the stock looks roughly 60.8% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $382.35 per share, and 20 of the 21 models we run sit above the $62.34 price.
Bear case: the Economic Profit group reads lowest at $118.13, and 1 of the 21 models stay below the price. Evidence for this calculation is low.
Scenario range: $79.50 (bear) to $288.23 (bull), the price of $62.34 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
PTC Therapeutics Inc reported revenue of $1.7B in FY2025 versus $539M in FY2021, a compound +33.9%/yr. Reported net income was $683M in FY2025.
Key figures
Market cap $7.0B · P/S ratio 8.51 · EPS (TTM) $−2.54 · Net margin 39.4% · Return on equity −7,740% · Return on assets (EBIT) −11.4% · Operating margin 16.5% · Revenue (TTM) $827M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 30% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 155%, PTCT screens cheaper than that median.
Fair Value models
Bear $79.50Fair Value $158.97Bull $288.23
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+114.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.4%
Start year 2020 (pandemic). Over 10 years: +47.0% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−113.4% (2020) → 49.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−7.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+0.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −10.0% a year for the price and −2.3% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (91 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score61 · Top 25%
Fair Value upside+155% · Top 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−2% · Above median
Net margin (TTM)−23% · Below median
Operating margin (TTM)17% · Top 25%
Growth and dividend
Revenue growth−77% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)8.51× · Pricier than median
P/FCF10.0× · Pricier than median
PEG0.81× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)100· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is PTC Therapeutics Inc (PTCT) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $158.97 versus a price of $62.34, about +155% upside (undervalued).
What is the fair value of PTCT?
Our model-based fair value for PTC Therapeutics Inc is $158.97 (as of Sep 23, 2026), built from audited fundamentals. The current price: $62.34.
What is the quality score of PTCT?
PTC Therapeutics Inc has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PTC Therapeutics Inc (PTCT)?
Our model-based price target is the fair value of $158.97 (as of Sep 23, 2026) from 21 valuation models. Cautious scenario $79.50, optimistic scenario $288.23. It is a calculation from audited fundamentals, not an analyst target.
What is the PTC Therapeutics Inc stock forecast for 2026?
Our models put fair value at $158.97, about +155% upside versus a price of $62.34 (undervalued). Cautious scenario $79.50, optimistic scenario $288.23. The calculation is refreshed regularly with new filings.
What is the revenue of PTC Therapeutics Inc (PTCT)?
PTC Therapeutics Inc reported trailing-twelve-month revenue of about $827M (latest available figure, as of Sep 23, 2026).
What growth is priced into PTC Therapeutics Inc (PTCT)?
For today's price to be fair in a discounted-cash-flow model, PTC Therapeutics Inc would have to grow free cash flow by -7.9 % per year for five years (discount rate 8.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +35.4 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of PTCT use?
Our models discount PTC Therapeutics Inc at 8.6 %: a base by market capitalisation (mid), damped by beta 0.53, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For PTC Therapeutics Inc that is -7.9 % per year a year over ten years, using the same discount rate (8.6 %) and the same formula as our fair value.
How much growth has PTC Therapeutics Inc (PTCT) delivered so far?
Over the past 5 years revenue at PTC Therapeutics Inc grew +35.4 % a year. The price currently implies -7.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of PTC Therapeutics Inc (PTCT) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into PTC Therapeutics Inc (-7.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of PTC Therapeutics Inc (PTCT)?
The free-cash-flow yield on the price is 12.76 %: that much free cash flow PTC Therapeutics Inc produces per unit of market value. When it exceeds the discount rate of our models (8.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of PTC Therapeutics Inc (PTCT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PTC Therapeutics Inc it is $158.97 per share (as of Sep 23, 2026), against a price of $62.34. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is PTC Therapeutics Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, PTCT trades below its calculated fair value: price $62.34, fair value $158.97, a gap of about +155% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PTCT?
No. The price is what the market pays today ($62.34); the fair value is what the company's own numbers justify ($158.97). For PTC Therapeutics Inc the two are $96.63 per share apart. That gap is exactly why we show both numbers side by side.
How much is PTC Therapeutics Inc worth?
The market values PTC Therapeutics Inc at about $7.0B (market capitalisation, as of Sep 23, 2026). Per share that is $62.34; our models calculate a fair value of $158.97 per share.
What do the bullish and bearish scenarios say about PTCT?
Our models span a range for PTC Therapeutics Inc: cautious scenario $79.50, base $158.97, optimistic $288.23 per share (as of Sep 23, 2026, price $62.34). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of PTCT?
The PEG ratio of PTC Therapeutics Inc is 0.81 (P/E divided by earnings growth, as of Sep 23, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of PTC Therapeutics Inc (PTCT)?
Balance-sheet figures for PTC Therapeutics Inc (as of Sep 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is PTCT from its 52-week high?
PTC Therapeutics Inc trades at $62.34, about 30% below its 52-week high of $89.55 and 8% above the low of $57.84 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $158.97 is for.
Which stocks are comparable to PTC Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PTC Therapeutics Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $62.34, calculated fair value $158.97 (+155%), Quality Score 61/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PTCT calculated?
We run PTC Therapeutics Inc through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $158.97, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. PTC Therapeutics Inc currently trades 155 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PTC Therapeutics Inc (PTCT)?
The closing price on Sep 23, 2026 was $62.34. Our model-based fair value is $158.97, about +155% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PTC Therapeutics Inc right now?
The price is below even our cautious bear case ($79.50). The market is more pessimistic than our downside scenario. The model range is unusually wide ($79.50 to $288.23). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of PTC Therapeutics Inc
How large is the market capitalisation of PTC Therapeutics Inc (PTCT)?
The market capitalisation of PTC Therapeutics Inc is $7.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of PTC Therapeutics Inc (PTCT)?
The price-to-sales ratio of PTC Therapeutics Inc is 8.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of PTC Therapeutics Inc (PTCT)?
Earnings per share at PTC Therapeutics Inc are $−2.54. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of PTC Therapeutics Inc (PTCT)?
The net margin of PTC Therapeutics Inc is 39.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of PTC Therapeutics Inc (PTCT)?
The return on equity (ROE) of PTC Therapeutics Inc is −7,740% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PTC Therapeutics Inc (PTCT)?
On an EBIT basis the return on assets of PTC Therapeutics Inc is −11.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PTC Therapeutics Inc (PTCT)?
The operating margin of PTC Therapeutics Inc is 16.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at PTC Therapeutics Inc (PTCT)?
Revenue at PTC Therapeutics Inc is growing −76.8% versus a year earlier (3y avg +35.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does PTC Therapeutics Inc (PTCT) hold?
PTC Therapeutics Inc holds more cash than debt, $492M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch PTC Therapeutics Inc in the live analysis
One click puts PTC Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026